Clinical and Biochemical Monitoring of Monocarboxylate Transporter 8 Deficiency (Allan-Herndon-Dudley Syndrome)
Johannes W Dietrich1,2,3,4,5, Evelyn Jelesch6, Michaela Linder-Lucht7
1Diabetes, Endocrinology and Metabolism Section, Department of Internal Medicine I, St. Josef University Hospital, Ruhr University Bochum, Bochum, Germany.
Abstract:
Pathogenic mutations in the SLC16A2 gene can result in partial or complete loss of function of the critical and highly specific monocarboxylate transporter 8 (MCT8), a thyroid hormone transporter. MCT8 deficiency (Allan-Herndon-Dudley syndrome) is a rare X-linked genetic disorder that causes profound neurodevelopmental delay, movement disorders, and peripheral thyrotoxicosis secondary to elevated serum tri-iodothyronine. The condition is chronic and life-limiting, with patients requiring regular multidisciplinary monitoring to manage their symptoms. This guideline proposes a comprehensive, multidisciplinary management strategy for healthcare professionals caring for patients with MCT8 deficiency across all age groups, monitoring key symptoms and sequelae. It highlights the substantial heterogeneity in symptoms and long-term outcomes associated with the condition, underscoring the need for individualized patient care plans.
More Related Videos
07:35Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
08:04Measuring Mitochondrial Electron Transfer Complexes in Previously Frozen Cardiac Tissue from the Offspring of Sow: A Model to Assess Exercise-Induced Mitochondrial Bioenergetics Changes
Published on: August 16, 2021
